Human medicines European public assessment report (EPAR): Camcevi, leuprorelin, Prostatic Neoplasms, Date of authorisation: 24/05/...
Camcevi is a medicine used in adult men for the treatment of advanced prostate cancer that is ‘hormone-dependent’, meaning that it responds to treatments that lower the level of the hormone testosterone. Camcevi is also used in combination with …